hydroxychloroquine has been researched along with Insulin Resistance in 10 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the effect of hydroxychloroquine (HCQ) on skeletal muscle and liver insulin sensitivity, insulin clearance, inflammation and adipokines." | 9.41 | The effects of hydroxychloroquine on insulin sensitivity, insulin clearance and inflammation in insulin-resistant adults: A randomized trial. ( DeLany, JP; Helbling, NL; Miller, RG; Toledo, FGS; Zhang, Y, 2021) |
| "Observational studies suggest that hydroxychloroquine (HCQ) may reduce the risk of developing diabetes mellitus in patients with rheumatoid arthritis (RA)." | 9.19 | Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial. ( Garg, R; Lu, B; Massarotti, E; Mercer, E; Norton, T; Solomon, DH; Todd, DJ, 2014) |
| " Hydroxychloroquine, an original antimalarial drug, prevents inflammation caused by lupus erythematosus and rheumatoid arthritis." | 7.83 | Hydroxychloroquine, a promising choice for coronary artery disease? ( Bai, X; Li, R; Liu, J; Liu, M; Ma, Q; Sun, L; Wei, Y; Wu, Y; Yang, Y; Yuan, Z; Zhang, L; Zhao, Q; Zhou, J, 2016) |
| "Hydroxychloroquine (HCQ) is a common disease modifying therapy for the treatment of rheumatoid arthritis (RA)." | 6.77 | Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals. ( Garg, R; Lu, B; Massarotti, EM; Mercer, E; Rekedal, L; Solomon, DH, 2012) |
| "Hydroxychloroquine (HCQ) has been demonstrated to reduce the risk to develop diabetes mellitus (DM)." | 5.43 | Favorable outcomes of hydroxychloroquine in insulin resistance may be accomplished by adjustment of the endothelial dysfunction as well as the skewed balance of adipokines. ( Abdel-Hamid, AAM; Firgany, AEL, 2016) |
| "To determine the effect of hydroxychloroquine (HCQ) on skeletal muscle and liver insulin sensitivity, insulin clearance, inflammation and adipokines." | 5.41 | The effects of hydroxychloroquine on insulin sensitivity, insulin clearance and inflammation in insulin-resistant adults: A randomized trial. ( DeLany, JP; Helbling, NL; Miller, RG; Toledo, FGS; Zhang, Y, 2021) |
| "Observational studies suggest that hydroxychloroquine (HCQ) may reduce the risk of developing diabetes mellitus in patients with rheumatoid arthritis (RA)." | 5.19 | Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial. ( Garg, R; Lu, B; Massarotti, E; Mercer, E; Norton, T; Solomon, DH; Todd, DJ, 2014) |
| " Hydroxychloroquine, an original antimalarial drug, prevents inflammation caused by lupus erythematosus and rheumatoid arthritis." | 3.83 | Hydroxychloroquine, a promising choice for coronary artery disease? ( Bai, X; Li, R; Liu, J; Liu, M; Ma, Q; Sun, L; Wei, Y; Wu, Y; Yang, Y; Yuan, Z; Zhang, L; Zhao, Q; Zhou, J, 2016) |
| "Among patients with RA or psoriasis, the adjusted risk of DM was lower for individuals starting a TNF inhibitor or hydroxychloroquine compared with initiation of other nonbiologic DMARDs." | 3.77 | Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. ( Canning, C; Garg, R; Liu, J; Massarotti, E; Schneeweiss, S; Solomon, DH, 2011) |
| "Hydroxychloroquine (HCQ) is a widely used antimalarial and anti-inflammatory drug and its hyperglycemia-controlling effect in diabetic patients is also under investigation." | 3.01 | Treating diabetes with combination of phosphodiesterase 5 inhibitors and hydroxychloroquine-a possible prevention strategy for COVID-19? ( Das, A; Koka, S; Kukreja, RC; Samidurai, A; Wang, R; Xi, L, 2023) |
| "Hydroxychloroquine (HCQ) is a common disease modifying therapy for the treatment of rheumatoid arthritis (RA)." | 2.77 | Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals. ( Garg, R; Lu, B; Massarotti, EM; Mercer, E; Rekedal, L; Solomon, DH, 2012) |
| "Hydroxychloroquine (HCQ) has been demonstrated to reduce the risk to develop diabetes mellitus (DM)." | 1.43 | Favorable outcomes of hydroxychloroquine in insulin resistance may be accomplished by adjustment of the endothelial dysfunction as well as the skewed balance of adipokines. ( Abdel-Hamid, AAM; Firgany, AEL, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kukreja, RC | 1 |
| Wang, R | 1 |
| Koka, S | 1 |
| Das, A | 1 |
| Samidurai, A | 1 |
| Xi, L | 1 |
| Chee, YJ | 1 |
| Tan, SK | 1 |
| Yeoh, E | 1 |
| Toledo, FGS | 1 |
| Miller, RG | 1 |
| Helbling, NL | 1 |
| Zhang, Y | 1 |
| DeLany, JP | 1 |
| Araiza-Casillas, R | 1 |
| Díaz-Molina, R | 1 |
| González-Ortiz, M | 1 |
| Robinson-Navarro, OM | 1 |
| Solomon, DH | 3 |
| Garg, R | 3 |
| Lu, B | 2 |
| Todd, DJ | 1 |
| Mercer, E | 2 |
| Norton, T | 1 |
| Massarotti, E | 2 |
| Wasko, MC | 1 |
| McClure, CK | 1 |
| Kelsey, SF | 1 |
| Huber, K | 1 |
| Orchard, T | 1 |
| Toledo, FG | 1 |
| Abdel-Hamid, AAM | 1 |
| Firgany, AEL | 1 |
| Sun, L | 1 |
| Liu, M | 1 |
| Li, R | 1 |
| Zhao, Q | 1 |
| Liu, J | 2 |
| Yang, Y | 1 |
| Zhang, L | 1 |
| Bai, X | 1 |
| Wei, Y | 1 |
| Ma, Q | 1 |
| Zhou, J | 1 |
| Yuan, Z | 1 |
| Wu, Y | 1 |
| Canning, C | 1 |
| Schneeweiss, S | 1 |
| Rekedal, L | 1 |
| Massarotti, EM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Hydroxychloroquine Assessment of Management Study in Coronary Artery Disease After Angiography.[NCT02874287] | Phase 4 | 35 participants (Actual) | Interventional | 2017-10-08 | Completed | ||
| Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis[NCT01132118] | Phase 3 | 30 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Mechanisms of Action of Hydroxychloroquine in Reducing Risk of Type 2 Diabetes[NCT01326533] | Phase 4 | 32 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| Impact of Rheumatoid Arthritis on Type 2 Diabetes Mellitus[NCT02639988] | 1,000 participants (Anticipated) | Observational | 2016-04-13 | Suspended | |||
| Assessing the Efficacy and Safety of Metformin in Treatment of Moderate Psoriasis: A Prospective Randomized Double Blind Controlled Study[NCT02644954] | Phase 3 | 40 participants (Anticipated) | Interventional | 2016-01-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
mg/dL (NCT01132118)
Timeframe: Baseline and Week 8
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Baseline | Period | Change | |
| Hydroxychloroquine | 58.1 | 59.4 | 1.3 |
| Placebo | 58.1 | 60.3 | 2.2 |
HOMA-B = (360 x Insulin)/(Glucose - 63) (NCT01132118)
Timeframe: Baseline and Week 8
| Intervention | (mIU x dL)/(L x mg) (Mean) | ||
|---|---|---|---|
| Baseline | Period | Change | |
| Hydroxychloroquine | 116.5 | 110.8 | -5.8 |
| Placebo | 116.5 | 109.7 | -6.8 |
"We will examine the effect of HCQ on HOMA-IR during the active treatment phase compared with placebo phase.~HOMA-IR = (Glucose x insulin)/405" (NCT01132118)
Timeframe: Baseline and Week 8
| Intervention | (mg x mIU)/(dL*L) (Mean) | ||
|---|---|---|---|
| Baseline | Period | Change | |
| Hydroxychloroquine | 2.0 | 1.7 | -0.3 |
| Placebo | 2.0 | 1.6 | -0.42 |
"We will examine the effect of HCQ on the Matsuda Insulin Sensitivity Index (ISI) during the active treatment phase compared with placebo phase.~ISI is based on insulin and glucose levels in a fasting state during an oral glucose tolerance test (OGTT) and is calculated as follows:~ISI (Matsuda) = 10000/√ G0 X I0 X Gmean X Imean~G0 - fasting plasma glucose (mg/dL) I0 - fasting plasma insulin (mIU/L) Gmean - mean plasma glucose during OGTT (mg/dL) Imean - mean plasma insulin during OGTT (mIU/L)" (NCT01132118)
Timeframe: Baseline and Week 8
| Intervention | (dL x L)/(mg x mIU) (Mean) | ||
|---|---|---|---|
| Baseline | Period Value | Change | |
| Hydroxychloroquine | 7.7 | 8.1 | 0.4 |
| Placebo | 7.7 | 7.8 | 0.14 |
mg/dL (NCT01132118)
Timeframe: Baseline and Week 8
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Baseline | Period | Change | |
| Hydroxychloroquine | 114.1 | 101.7 | -12.4 |
| Placebo | 114.1 | 109.9 | -4.2 |
mg/dL (NCT01132118)
Timeframe: Baseline and Week 8
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Baseline | Period | Change | |
| Hydroxychloroquine | 192.4 | 179.7 | -12.7 |
| Placebo | 192.4 | 189.4 | -3.0 |
mg/dL (NCT01132118)
Timeframe: Baseline and Week 8
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Baseline | Period | Change | |
| Hydroxychloroquine | 100.6 | 92.4 | -8.2 |
| Placebo | 100.6 | 95.6 | -5.0 |
Change from baseline in the disposition index (DI) (NCT01326533)
Timeframe: 13 weeks after baseline measurement
| Intervention | arbitrary units (Mean) |
|---|---|
| Hydroxychloroquine | 352 |
| Placebo | -218 |
Change from baseline in the insulin sensitivity index (Si) (NCT01326533)
Timeframe: 13 weeks after baseline measurement
| Intervention | 10^-4/pmol*l/min (Mean) |
|---|---|
| Hydroxychloroquine | 0.08 |
| Placebo | -0.11 |
2 reviews available for hydroxychloroquine and Insulin Resistance
| Article | Year |
|---|---|
Treating diabetes with combination of phosphodiesterase 5 inhibitors and hydroxychloroquine-a possible prevention strategy for COVID-19?
Topics: Animals; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type | 2023 |
Dissecting the interaction between COVID-19 and diabetes mellitus.
Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; Blood Glucose; Chloroquine; Comorbidity; COVID- | 2020 |
5 trials available for hydroxychloroquine and Insulin Resistance
| Article | Year |
|---|---|
The effects of hydroxychloroquine on insulin sensitivity, insulin clearance and inflammation in insulin-resistant adults: A randomized trial.
Topics: Adult; Diabetes Mellitus, Type 2; Humans; Hydroxychloroquine; Inflammation; Insulin; Insulin Resista | 2021 |
[Effects of hydroxychloroquine on insulin sensitivity and lipid profile in patients with rheumatoid arthritis].
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Glucose; Body Mass Index; Cholesterol; Fem | 2013 |
Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cross-Over Studies; Diabetes Mellitus, Type 2; Do | 2014 |
Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cross-Over Studies; Diabetes Mellitus, Type 2; Do | 2014 |
Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cross-Over Studies; Diabetes Mellitus, Type 2; Do | 2014 |
Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cross-Over Studies; Diabetes Mellitus, Type 2; Do | 2014 |
Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trial.
Topics: Adult; Blood Glucose; Cytokines; Double-Blind Method; Female; Humans; Hydroxychloroquine; Insulin; I | 2015 |
Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals.
Topics: Antirheumatic Agents; Body Mass Index; Female; Humans; Hydroxychloroquine; Insulin Resistance; Longi | 2012 |
3 other studies available for hydroxychloroquine and Insulin Resistance
| Article | Year |
|---|---|
Favorable outcomes of hydroxychloroquine in insulin resistance may be accomplished by adjustment of the endothelial dysfunction as well as the skewed balance of adipokines.
Topics: Adipokines; Animals; Diet, High-Fat; Endothelial Cells; Hydroxychloroquine; Insulin Resistance; Insu | 2016 |
Hydroxychloroquine, a promising choice for coronary artery disease?
Topics: Animals; Antimalarials; Arthritis, Rheumatoid; Coronary Artery Disease; Disease Models, Animal; Huma | 2016 |
Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Canada; Cohort Studies; Diabetes Mellitus; Female | 2011 |
Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Canada; Cohort Studies; Diabetes Mellitus; Female | 2011 |
Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Canada; Cohort Studies; Diabetes Mellitus; Female | 2011 |
Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Canada; Cohort Studies; Diabetes Mellitus; Female | 2011 |